北京阳光诺和药物研究股份有限公司关于自愿披露共建联合实验室的公告

Core Viewpoint - Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. has signed an agreement with Peking University Health Science Center to establish the "Peking University Medicine - Sunshine Nuohuo Innovative Drug Joint Laboratory," focusing on cutting-edge fields such as cell therapy and gene therapy to develop clinical candidate drugs [1][2]. Group 1: Overview of Cooperation - The collaboration aims to enhance independent innovation capabilities and national core competitiveness, promoting quality improvement in innovative research and development [2]. - The partnership does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1]. Group 2: Basic Information of Partners - Peking University Health Science Center is the first western medical school established by the Chinese government and is part of the "211 Project," with a strong foundation in teaching, research, and medical education [3]. - There are no existing relationships of dishonesty or conflicts of interest between the partners [4]. Group 3: Main Content of the Cooperation Agreement - The agreement outlines that Peking University will organize research efforts, while Sunshine Nuohuo will provide funding and address technical challenges [5][6]. - The laboratory will focus on developing world-class clinical candidate drugs, including innovative therapies in cell and gene treatment [7][10]. Group 4: Funding and Management - Sunshine Nuohuo will provide a total of RMB 20 million (approximately 2 million) for the laboratory's operation, with an initial funding of RMB 10 million (approximately 1 million) to be transferred within 30 working days of the agreement [9]. - The intellectual property rights from the research conducted in the laboratory will be jointly owned by both parties, typically shared equally [9]. Group 5: Impact on the Company - This collaboration is a strategic move to deepen the company's innovation in drug development and enhance its core competitiveness, leveraging Peking University's research strengths and Sunshine Nuohuo's capabilities in drug development and commercialization [12]. - The funding for this partnership will come from the company's own resources, ensuring no adverse impact on cash flow or existing operations [12].